NCT00262288View on ClinicalTrials.gov

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Genetic Disorders
Interventions
DRUG

i.v. recombinant human C1 inhibitor

Trial Locations (1)

2333 CN

For information on sites in Europe, please contact Pharming Technologies., Leiden

Sponsors
All Listed Sponsors
lead

Pharming Technologies B.V.

INDUSTRY

NCT00262288 - Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Biotech Hunter | Biotech Hunter